NEW DELHI: Efficacy analysis of Covaxin demonstrates that the vaccine to be 77.8 percent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials. Efficacy analysis also demonstrates Covaxin to be 93.4 percent effective against severe symptomatic COVID-19.

Safety analysis demonstrates adverse events reported were similar to placebo, with 12 percent of subjects experiencing commonly known side effects and less than 0.5 percent of subjects feeling serious adverse events. The data demonstrates 63.6 percent protection against asymptomatic COVID-19 and efficacy data demonstrates 65.2 percent protection against the SARS-CoV-2, B.1.617.2 Delta variant.

Phase 3 clinical trials of COVAXIN was an event driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India. Covaxin is formulated with a novel Algel+IMDG adjuvant. IMDG is a TLR7/8 agonist known to induce memory T cell responses along with strong neutralizing antibodies.

Study reveals Covid-19 first wave led to increase in antibiotic misuse in India:

Health Ministry deploys high-level team of experts to check rising cases in 6 states

Study suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2